BRAVE-AA2

Phase 3, randomised, double-blind, placebo-controlled clinical trial with 546 adult participants with severe alopecia areata, which assessed baricitinib against placebo. The primary endpoint was the percentage of patients with SALT ≤20 at week 36 (35.9% with 4 mg, 19.4% with 2 mg and 3.3% with placebo).

Institutional endorsement by Clínica Evolution

This entry is for information. Your case requires an individual medical assessment.